Figure 2: Tumour type-specific signatures for NMD-elicit mutations in tumour suppressor genes. | Nature Communications

Figure 2: Tumour type-specific signatures for NMD-elicit mutations in tumour suppressor genes.

From: A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay

Figure 2

(a) Boxplots showing the expression levels of the indicated genes categorized by the type of mutations. NMD-elicit includes NMD-elicit frameshift insertions/deletions (indels) and nonsense mutations; non-NMD includes frameshift and nonsense mutations that are not NMD-elicit. The genes harbouring NMD-elicit mutations have significantly lower expression than the genes harbouring non-NMD or missense mutations (median ratio of REV=0.07 for NF1, 0.06 for TP53; P<2.2e−16, one-side MWW test). The missense is the missense mutation. For TP53, the numbers in each group correspond to 39, 642 and 1,675. For NF1, the numbers in each group correspond to 2, 171 and 177. (b) A barplot representation of the percentage of samples harbouring NMD-elicit TSGs (x axis) across cancer types (y axis). (c) A heatmap indicating mutations of genes (rows) across samples (columns) as NMD-elicit (orange), non-NMD-elicit and non-silent (green) or others (grey). Samples were organized by cancer type as indicated in the legend.

Back to article page